Enorama Pharma AB (publ) (ERMA.ST)
SEK 2.95
(3.15%)
SEK 2.95
(3.15%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 436 Thousand SEK | -77.16% |
| 2022 | 1.9 Million SEK | -49.62% |
| 2021 | 3.78 Million SEK | -33.63% |
| 2020 | 5.7 Million SEK | 0.0% |
| 2019 | - SEK | -100.0% |
| 2018 | 1.55 Million SEK | -52.31% |
| 2017 | 3.25 Million SEK | -8.45% |
| 2016 | 3.55 Million SEK | 317.65% |
| 2015 | 850 Thousand SEK | 41.67% |
| 2014 | 600 Thousand SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 368 Thousand SEK | -8.68% |
| 2024 Q1 | 403 Thousand SEK | -7.57% |
| 2023 FY | 436 Thousand SEK | -77.16% |
| 2023 Q3 | 463 Thousand SEK | -29.2% |
| 2023 Q4 | 436 Thousand SEK | -5.83% |
| 2023 Q2 | 654 Thousand SEK | -46.79% |
| 2023 Q1 | 1.22 Million SEK | -35.62% |
| 2022 FY | 1.9 Million SEK | -49.62% |
| 2022 Q4 | 1.9 Million SEK | -14.09% |
| 2022 Q3 | 2.22 Million SEK | -19.02% |
| 2022 Q2 | 2.74 Million SEK | -15.98% |
| 2022 Q1 | 3.26 Million SEK | -13.8% |
| 2021 Q2 | 4.83 Million SEK | -9.73% |
| 2021 Q1 | 5.35 Million SEK | -6.22% |
| 2021 Q4 | 3.78 Million SEK | -12.11% |
| 2021 Q3 | 4.31 Million SEK | -10.8% |
| 2021 FY | 3.78 Million SEK | -33.63% |
| 2020 Q1 | - SEK | 0.0% |
| 2020 Q4 | 5.7 Million SEK | 14.18% |
| 2020 Q3 | 5 Million SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 FY | 5.7 Million SEK | 0.0% |
| 2019 Q4 | - SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 Q2 | - SEK | -100.0% |
| 2019 Q1 | 750 Thousand SEK | -51.61% |
| 2019 FY | - SEK | -100.0% |
| 2018 Q3 | 2.35 Million SEK | -24.19% |
| 2018 Q2 | 3.1 Million SEK | -72.32% |
| 2018 FY | 1.55 Million SEK | -52.31% |
| 2018 Q4 | 1.55 Million SEK | -34.04% |
| 2018 Q1 | 11.2 Million SEK | 244.62% |
| 2017 Q4 | 3.25 Million SEK | -1.52% |
| 2017 Q2 | 3.35 Million SEK | -3.6% |
| 2017 Q1 | 3.47 Million SEK | -2.11% |
| 2017 FY | 3.25 Million SEK | -8.45% |
| 2017 Q3 | 3.3 Million SEK | -1.49% |
| 2016 FY | 3.55 Million SEK | 317.65% |
| 2016 Q2 | 3.7 Million SEK | 278.32% |
| 2016 Q4 | 3.55 Million SEK | -2.07% |
| 2016 Q1 | 978 Thousand SEK | 15.06% |
| 2016 Q3 | 3.62 Million SEK | -2.03% |
| 2015 Q4 | 850 Thousand SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 FY | 850 Thousand SEK | 41.67% |
| 2014 FY | 600 Thousand SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| BioGaia AB (publ) | 8.8 Million SEK | 95.045% |
| Enzymatica AB (publ) | 26.1 Million SEK | 98.33% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | 18.93 Million SEK | 97.697% |
| Moberg Pharma AB (publ) | 4.73 Million SEK | 90.796% |
| Nanexa AB (publ) | 4.03 Million SEK | 89.187% |
| Newbury Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| ODI Pharma AB | - SEK | -Infinity% |
| Orexo AB (publ) | 473.8 Million SEK | 99.908% |
| Probi AB (publ) | 53.79 Million SEK | 99.19% |
| Swedencare AB (publ) | 1.65 Billion SEK | 99.974% |
| Swedish Orphan Biovitrum AB (publ) | 20.48 Billion SEK | 99.998% |
| Toleranzia AB | 850 Thousand SEK | 48.706% |
| Vivesto AB | 8.16 Million SEK | 94.662% |